Physician profile
Geralda Vilus
NPI 1407201627
$1,135.62
in general payments reported to CMS, 2019-2025
12 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $101 · 2023: $408 · 2024: $329 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $303.37 | 2021-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $239.46 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $116.18 | 2021-2025 | Ingrezza |
| Abbvie INC. | $113.84 | 2021-2023 | |
| Indivior INC. | $92.52 | 2021-2024 | Perseris |
| Alkermes, INC. | $84.25 | 2021-2025 | Lybalvi, Vivitrol, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $69.01 | 2021-2024 | Abilify Asimtufii, Abilify Maintena |
| Bioxcel Therapeutics, INC. | $47.28 | 2023 | Igalmi |
| E.R. Squibb & Sons, L.L.C. | $25.25 | 2024 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.99 | 2024 | Caplyta |
| Braeburn INC. | $14.55 | 2024 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geralda Vilus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.